Indivior rallies on US approval of opioid treatment
Addiction specialist Indivior (INDV) is enjoying a 9.9% rally to 407.4p following the approval of its Sublocade injectable drug, also known as RBP-6000, by the US Food and Drug Administration (FDA).The share price jump suggests...
01 December 2017
